POXEL Enters Agreement with SCYNEXIS for Sale of PXL770
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 10 hours ago
0mins
Should l Buy SCYX?
POXEL (PXXLF) entered into a definitive agreement with SCYNEXIS (SCYX) in connection with the sale of its drug candidate PXL770. PXL-770 is a novel, highly selective, direct AMPK activator developed for the treatment of autosomal dominant polycystic kidney disease, the leading genetic cause of end-stage renal disease. This product has been designed to act on several underlying mechanisms of ADPKD by reducing cyst growth and disease progression. PXL770 has been granted orphan drug designation by the U.S. Food and Drug Administration and is protected by existing patents until at least 2041. To date, ADPKD has only one approved treatment, Jynarque, which generated approximately $1.5B in sales in the U.S. in 2024, despite limited patient adoption due to safety, tolerability, and follow-up constraints. Under the terms of the asset disposal agreement, SCYNEXIS will make an upfront payment of $8M to Poxel SA, to which may be added future payments of up to $188M triggered based on the completion of various clinical and commercial milestones. SCYNEXIS expects to initiate a Phase 2 proof-of-concept study in patients with ADPKD in the fourth quarter of 2026, with a first efficacy reading expected in the second half of 2027. It is specified that IPF, as the first beneficiary of Trust 3 which has owned the PXL770 asset since September 30, 2024, authorized the transfer of this asset to the assets of POXEL SA for sale to Scynexis. In return, IPF will receive 75% of the amounts paid by Scynexis which will be allocated to the repayment of its debt. However, IPF has agreed that a portion of the amounts received in respect of the upfront payment and the 2 clinical milestone payments will be set aside for Poxel, to secure the future financing of the company. These amounts may be used according to the company's future needs and under the conditions defined in the Tranche D PDR documentation. Also, Poxel will have the option to cancel these additional commitments within three months of their availability, if the company considers that they are no longer necessary.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SCYX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SCYX
Wall Street analysts forecast SCYX stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.790
Low
3.00
Averages
3.50
High
4.00
Current: 0.790
Low
3.00
Averages
3.50
High
4.00
No data
About SCYX
SCYNEXIS, Inc. is a biotechnology company. It is pioneering medicine to overcome and prevent difficult-to-treat and drug-resistant infections. It is developing its antifungal platform fungerps, a class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have shown in vitro and in vivo activity against a range of human fungal pathogens such as Candida and Aspergillus genera, including multidrug-resistant strains, as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and common mucorales species. Ibrexafungerp is the first representative of this class of antifungals with additional assets from the fungerp family under development, including SCY-247, which is in clinical stages of development. The United States Food and Drug Administration approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis, and for the reduction in the incidence of recurrent vulvovaginal candidiasis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
SCYNEXIS Secures $40M in Securities Purchase Agreement
- Financing Agreement Details: SCYNEXIS has entered into a securities purchase agreement with institutional investors, anticipating upfront gross proceeds of approximately $40M, with an additional $52.2M available if common warrants are fully exercised, indicating strong market confidence in its future.
- Share Issuance Plan: The company will issue 34.75M shares of common stock and 8.75M pre-funded warrants, along with common warrants for 43.5M shares, reflecting a proactive adjustment in its capital structure aimed at enhancing liquidity.
- Use of Proceeds: The net proceeds from this financing will be allocated for working capital and general corporate purposes, with estimates suggesting that these funds will support operations into mid-2029, ensuring ongoing investment in R&D and market expansion.
- Market Reaction: SCYNEXIS's stock rose 3.83% in pre-market trading to $0.82, reflecting positive investor sentiment towards the company's financing strategy and recognition of its growth potential.
See More
Poxel Enters Drug Agreement with SCYNEXIS for PXL770
- Financial Terms: Poxel has entered into an agreement with SCYNEXIS, which includes an upfront payment of $8 million and potential future payments of up to $188 million based on clinical and commercial milestones, significantly enhancing Poxel's financial position.
- Clinical Trial Timeline: A Phase 2 proof-of-concept study for PXL770 is expected to begin in Q4 2026, with the first efficacy review anticipated in the second half of 2027, which will drive innovation in the ADPKD treatment landscape.
- Market Potential: As the first direct AMPK activator, PXL770 aims to reduce cyst growth and slow ADPKD progression, presenting a substantial market opportunity, especially given the limited adoption of the currently available treatment, Jynarque®.
- Strategic Partnership Impact: Poxel's CEO highlighted that the collaboration with SCYNEXIS will unlock the full therapeutic potential of PXL770, allowing the company to focus on developing TWYMEEG® and PXL065, thereby creating additional value for stakeholders.
See More
Scynexis Acquires Kidney Disease Treatment, Shares Surge
- Stock Surge: Scynexis, Inc. (SCYX) shares rose approximately 10% in pre-market trading on Tuesday, primarily driven by the announcement of a deal to acquire a potential kidney disease treatment from Poxel S.A.
- Acquisition Details: Scynexis signed a definitive agreement to acquire PXL-770, now renamed SCY-770, a novel oral therapy aimed at treating Autosomal Dominant Polycystic Kidney Disease, a leading cause of kidney failure.
- Clinical Trial Progress: The drug has demonstrated a favorable safety profile across eight clinical trials, with plans to initiate a Phase 2 study in late 2026 and early results expected in the second half of 2027.
- Funding Strategy: Scynexis expects to raise about $40 million upfront from a private placement, with the potential for an additional $52.2 million if all warrants are exercised for cash, thereby strengthening its financial position to support ongoing research and development.
See More
Poxel SA Sells Drug Candidate PXL770 to Scynexis for Up to $196 Million
- Significant Transaction Value: Poxel SA has agreed to sell its drug candidate PXL770 to Scynexis for up to $196 million, including an upfront payment of $8 million and additional payments tied to development and commercial milestones, indicating strong market recognition of the drug's potential.
- Clinical Trial Plans: A Phase 2 proof-of-concept study for autosomal dominant polycystic kidney disease is expected to begin in Q4 2026, with initial efficacy results anticipated in the second half of 2027, which will provide critical data for further drug development.
- Focus on Core Pipeline: Poxel SA plans to concentrate on its core pipeline, including TWYMEEG and PXL065, while pursuing new partnerships to create long-term value, demonstrating a strategic emphasis on the ongoing advancement of drug development.
- Positive Market Reaction: Poxel SA's stock rose 9.78% to €0.2525 on the Paris Stock Exchange, while Scynexis saw a 4.76% increase to $0.8273 in pre-market trading on Nasdaq, reflecting investor optimism regarding the transaction.
See More
SCYNEXIS Reports 2025 Financial Highlights and Pipeline Progress
- Significant Revenue Growth: SCYNEXIS reported total revenue of $20.6 million for 2025, a substantial increase from $3.7 million in 2024, primarily driven by licensing agreement revenue from GSK, indicating strong performance in the antifungal market.
- Narrowed Net Loss: The company posted a net loss of $8.6 million in 2025, significantly down from $21.3 million in 2024, reflecting effective cost control and revenue growth, which enhances investor confidence.
- SCY-247 Clinical Progress: SCY-247, a second-generation antifungal drug, is currently in Phase 1 clinical trials, with early results demonstrating good tolerability and strong pharmacokinetics, with topline data for the IV formulation expected in the second half of 2026.
- BREXAFEMME Relaunch Plans: Despite the recall of BREXAFEMME in 2023 due to manufacturing issues, GSK is preparing for its relaunch, and SCYNEXIS stands to gain up to $145.5 million in annual net sales milestones and royalties, further strengthening its financial stability.
See More
SCYNEXIS Secures FDA QIDP Designation for SCY-247, Ensuring 10 Years of Market Exclusivity
- FDA Designation: SCYNEXIS's SCY-247 has received QIDP and Fast Track designations from the FDA, ensuring at least 10 years of market exclusivity post-approval, thereby enhancing the company's competitive edge in the antifungal market.
- Clinical Trial Plans: The company expects to initiate a Phase 1 study of SCY-247 with the IV formulation and a Phase 2 study with the oral formulation in 2026, aiming to address the treatment needs for invasive candidiasis and further advance product development.
- Antifungal Activity: SCY-247 has demonstrated potent activity against various difficult-to-treat fungal pathogens, including multi-drug-resistant Candida auris, in multiple preclinical studies, indicating its potential to combat public health threats.
- Market Demand: As the threat of multi-drug resistant fungal infections escalates, the development of SCY-247 not only meets the urgent market need for novel antifungal agents but also holds the potential for significant economic returns for the company.
See More
SCYNEXIS Secures $40M in Securities Purchase Agreement
- Financing Agreement Details: SCYNEXIS has entered into a securities purchase agreement with institutional investors, anticipating upfront gross proceeds of approximately $40M, with an additional $52.2M available if common warrants are fully exercised, indicating strong market confidence in its future.
- Share Issuance Plan: The company will issue 34.75M shares of common stock and 8.75M pre-funded warrants, along with common warrants for 43.5M shares, reflecting a proactive adjustment in its capital structure aimed at enhancing liquidity.
- Use of Proceeds: The net proceeds from this financing will be allocated for working capital and general corporate purposes, with estimates suggesting that these funds will support operations into mid-2029, ensuring ongoing investment in R&D and market expansion.
- Market Reaction: SCYNEXIS's stock rose 3.83% in pre-market trading to $0.82, reflecting positive investor sentiment towards the company's financing strategy and recognition of its growth potential.
See More
Poxel Enters Drug Agreement with SCYNEXIS for PXL770
- Financial Terms: Poxel has entered into an agreement with SCYNEXIS, which includes an upfront payment of $8 million and potential future payments of up to $188 million based on clinical and commercial milestones, significantly enhancing Poxel's financial position.
- Clinical Trial Timeline: A Phase 2 proof-of-concept study for PXL770 is expected to begin in Q4 2026, with the first efficacy review anticipated in the second half of 2027, which will drive innovation in the ADPKD treatment landscape.
- Market Potential: As the first direct AMPK activator, PXL770 aims to reduce cyst growth and slow ADPKD progression, presenting a substantial market opportunity, especially given the limited adoption of the currently available treatment, Jynarque®.
- Strategic Partnership Impact: Poxel's CEO highlighted that the collaboration with SCYNEXIS will unlock the full therapeutic potential of PXL770, allowing the company to focus on developing TWYMEEG® and PXL065, thereby creating additional value for stakeholders.
See More
Scynexis Acquires Kidney Disease Treatment, Shares Surge
- Stock Surge: Scynexis, Inc. (SCYX) shares rose approximately 10% in pre-market trading on Tuesday, primarily driven by the announcement of a deal to acquire a potential kidney disease treatment from Poxel S.A.
- Acquisition Details: Scynexis signed a definitive agreement to acquire PXL-770, now renamed SCY-770, a novel oral therapy aimed at treating Autosomal Dominant Polycystic Kidney Disease, a leading cause of kidney failure.
- Clinical Trial Progress: The drug has demonstrated a favorable safety profile across eight clinical trials, with plans to initiate a Phase 2 study in late 2026 and early results expected in the second half of 2027.
- Funding Strategy: Scynexis expects to raise about $40 million upfront from a private placement, with the potential for an additional $52.2 million if all warrants are exercised for cash, thereby strengthening its financial position to support ongoing research and development.
See More
Poxel SA Sells Drug Candidate PXL770 to Scynexis for Up to $196 Million
- Significant Transaction Value: Poxel SA has agreed to sell its drug candidate PXL770 to Scynexis for up to $196 million, including an upfront payment of $8 million and additional payments tied to development and commercial milestones, indicating strong market recognition of the drug's potential.
- Clinical Trial Plans: A Phase 2 proof-of-concept study for autosomal dominant polycystic kidney disease is expected to begin in Q4 2026, with initial efficacy results anticipated in the second half of 2027, which will provide critical data for further drug development.
- Focus on Core Pipeline: Poxel SA plans to concentrate on its core pipeline, including TWYMEEG and PXL065, while pursuing new partnerships to create long-term value, demonstrating a strategic emphasis on the ongoing advancement of drug development.
- Positive Market Reaction: Poxel SA's stock rose 9.78% to €0.2525 on the Paris Stock Exchange, while Scynexis saw a 4.76% increase to $0.8273 in pre-market trading on Nasdaq, reflecting investor optimism regarding the transaction.
See More
SCYNEXIS Reports 2025 Financial Highlights and Pipeline Progress
- Significant Revenue Growth: SCYNEXIS reported total revenue of $20.6 million for 2025, a substantial increase from $3.7 million in 2024, primarily driven by licensing agreement revenue from GSK, indicating strong performance in the antifungal market.
- Narrowed Net Loss: The company posted a net loss of $8.6 million in 2025, significantly down from $21.3 million in 2024, reflecting effective cost control and revenue growth, which enhances investor confidence.
- SCY-247 Clinical Progress: SCY-247, a second-generation antifungal drug, is currently in Phase 1 clinical trials, with early results demonstrating good tolerability and strong pharmacokinetics, with topline data for the IV formulation expected in the second half of 2026.
- BREXAFEMME Relaunch Plans: Despite the recall of BREXAFEMME in 2023 due to manufacturing issues, GSK is preparing for its relaunch, and SCYNEXIS stands to gain up to $145.5 million in annual net sales milestones and royalties, further strengthening its financial stability.
See More
SCYNEXIS Secures FDA QIDP Designation for SCY-247, Ensuring 10 Years of Market Exclusivity
- FDA Designation: SCYNEXIS's SCY-247 has received QIDP and Fast Track designations from the FDA, ensuring at least 10 years of market exclusivity post-approval, thereby enhancing the company's competitive edge in the antifungal market.
- Clinical Trial Plans: The company expects to initiate a Phase 1 study of SCY-247 with the IV formulation and a Phase 2 study with the oral formulation in 2026, aiming to address the treatment needs for invasive candidiasis and further advance product development.
- Antifungal Activity: SCY-247 has demonstrated potent activity against various difficult-to-treat fungal pathogens, including multi-drug-resistant Candida auris, in multiple preclinical studies, indicating its potential to combat public health threats.
- Market Demand: As the threat of multi-drug resistant fungal infections escalates, the development of SCY-247 not only meets the urgent market need for novel antifungal agents but also holds the potential for significant economic returns for the company.
See More
